Where Data Tells the Story
© Voronoi 2026. All rights reserved.
This chart captures the evolving DNA of Stan Druckenmiller Q3 2025 13F. It compares Druckenmiller’s top holdings in Q3 2015 vs. Q3 2025, revealing a dramatic pivot from tech and finance giants to biotech innovators and global disruptors. In 2015, Meta alone made up 31.3% of his portfolio. By 2025, Natera, Insmed, and Teva lead the charge, with emerging players like Coupang, MercadoLibre, and Verona Pharma gaining ground.
🧠 Takeaway:
Druckenmiller’s portfolio reflects a shift from platform dominance to frontier innovation — betting on biotech breakthroughs and global consumer expansion.
📊 Analysis: